Daewoong Pharmaceutical, Sears Technology, and Exo Systems Sign MOU for Joint Development of Integrated Smart Ward Solution

Applicable for Sarcopenia Diagnosis in Clinical Settings

Daewoong Pharmaceutical announced on December 11 that it has signed a three-party memorandum of understanding (MOU) with Sears Technology and Exo Systems at its headquarters in Gangnam-gu, Seoul, for the joint development and commercialization of a smart hospital bed monitoring system.

(From left) Lee Homan, CEO of ExoSystems, Changjae Lee, CEO of Daewoong Pharmaceutical, and Youngshin Lee, CEO of Sears Technology, are posing for a commemorative photo after signing a business agreement. Daewoong Pharmaceutical

Through this agreement, it is expected that the digital healthcare technology 'thynC' will be combined with a technology that collects muscle activation signals. In the future, this will enable the implementation of an integrated smart ward solution that can be used for diagnosing sarcopenia in clinical settings.

Under the agreement, Daewoong Pharmaceutical will promote the adoption of the solution to hospitals and medical institutions, and will be responsible for overall business operations including marketing activities, holding business briefings, and attracting new hospitals. Sears Technology will lead the joint development of an integrated platform that connects its AI-based bed monitoring system 'thynC' with Exo Systems' muscle activation signal analysis solution 'ExoPhil.' Exo Systems will ensure the technical stability of the ExoPhil device and promote productization and commercialization for hospital applications.

Previously, major tests for inpatients, including muscle function assessments, were typically conducted in examination rooms outside the hospital ward. Patients experienced inconvenience during the transfer process to the examination room, and the workload for medical staff responsible for these tasks continued to increase.

ExoPhil is a wearable medical device developed by Exo Systems based on proprietary biosignal collection technology, capable of delivering physiological electrical stimulation to the body. The newly developed thynC-ExoPhil integrated solution will add muscle activation signals to existing data such as blood pressure, blood glucose, electrocardiogram, oxygen saturation, and body temperature, enabling a more comprehensive assessment of inpatients' conditions. Notably, the key feature is that patients can receive muscle function assessments and electrical therapy simultaneously at their bedside without the need to move.

This is expected not only to enhance patient convenience but also to significantly reduce the workload of medical staff, thereby dramatically improving the operational efficiency of smart wards. It will allow for the establishment of a more systematic treatment system, and can be utilized in various departments such as neurology, neurosurgery, and rehabilitation medicine, improving both hospital work efficiency and patient safety.

Lee Changjae, CEO of Daewoong Pharmaceutical, said, "This three-party collaboration will set a new standard in the smart ward platform sector," adding, "We will continue to introduce digital healthcare solutions that deliver real value to medical sites by integrating the core competencies of each company."

This content was produced with the assistance of AI translation services.